Cite
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
MLA
Ghulam Warsi, et al. “Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma.” Experimental Hematology & Oncology, vol. 7, May 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5d15bf99991b8c85e31c2e1e815fbb14&authtype=sso&custid=ns315887.
APA
Ghulam Warsi, Lauren Pinter-Brown, Patrick B. Johnston, Kristen White, & Radhakrishnan Ramchandren. (2018). Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Experimental Hematology & Oncology, 7.
Chicago
Ghulam Warsi, Lauren Pinter-Brown, Patrick B. Johnston, Kristen White, and Radhakrishnan Ramchandren. 2018. “Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma.” Experimental Hematology & Oncology 7 (May). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5d15bf99991b8c85e31c2e1e815fbb14&authtype=sso&custid=ns315887.